A Phase II clinical trial of MN-166 (ibudilast) for glioblastoma in combination with an immune checkpoint inhibitor
Latest Information Update: 15 Jan 2021
At a glance
- Drugs Ibudilast (Primary) ; Immune checkpoint protein inhibitors (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors MediciNova
- 15 Jan 2021 New trial record
- 11 Jan 2021 According to a MediciNova media release, company enters into US$20 million securities purchase agreement with a fund managed by 3D investment partners. This find will be used for this study.